Compare ARK Genomic Revolution ETF (ARKG) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Pfizer Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Pfizer Inc trades at $24.24 (market cap $137.76B). The key difference: Pfizer Inc pays a 7.12% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $28.56 |
52-Week Low | $23.09 | $23.29 |
Market Cap | — | $137.76B |
Volume | — | 29,869,932 |
Enterprise Value | — | $188.41B |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Pfizer (PFE) trades at $24.17, down 0.33% on the day, with a bearish technical signal and neutral oscillators. The company maintains solid fundamentals with a P/E of 18.45, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline developments in obesity and oncology, with a $0.43 quarterly dividend providing income stability.
The outlook remains mixed: analyst consensus targets $27.63 (14% upside) but technicals suggest near-term pressure. Key risks include patent cliffs and competitive threats, while institutional sentiment leans hold. Valuation appears reasonable relative to cash flow generation, making PFE a defensive play with moderate growth potential amid ongoing pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
